<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596631</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4437</org_study_id>
    <secondary_id>U1111-1218-1527</secondary_id>
    <secondary_id>2018-002952-34</secondary_id>
    <nct_id>NCT04596631</nct_id>
  </id_info>
  <brief_title>A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes</brief_title>
  <acronym>PIONEER TEENS</acronym>
  <official_title>Efficacy and Safety of Oral Semaglutide Versus Placebo Both in Combination With Metformin and/or Basal Insulin in Children and Adolescents With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy&#xD;
      medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy&#xD;
      medicine. The study will also test if semaglutide is safe in children and teenagers.&#xD;
      Participants will either get semaglutide or the dummy medicine - which one is decided by&#xD;
      chance. Participants will take 1 tablet of the study medicine every morning on an empty&#xD;
      stomach. They have to wait 30 minutes before they eat, drink or take any other medication by&#xD;
      mouth. The study will last for about 1 year and 3 months (66 weeks). Participants will have&#xD;
      12 clinic visits and 8 phone calls with the study doctor. At all 12 clinic visits,&#xD;
      participants will have blood samples taken. Participants will also be asked some questions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">February 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Percentage point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body mass index (BMI) standard deviation score (SDS)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>SDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Percentage point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in body weight</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in body weight</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BMI SDS</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>SDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI percentile (age and gender adjusted)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI percentile (age and gender adjusted)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0% (53 mmol/mol) (yes/no), American Diabetes Association (ADA) target and International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines from 2018</measure>
    <time_frame>At week 26</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c equal to or below 6.5% (48 mmol/mol) (yes/no), American Association of Clinical Endocrinologists (AACE) target</measure>
    <time_frame>At week 26</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0% (53 mmol/mol) (yes/no), ADA target and ISPAD guidelines from 2018</measure>
    <time_frame>At week 52</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c equal to or below 6.5% (48 mmol/mol) (yes/no), AACE targetat week 26</measure>
    <time_frame>At week 52</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to additional anti-diabetic medication (to support the treatment policy estimand)</measure>
    <time_frame>Week 0 - week 52</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication (to support the hypothetical estimand)</measure>
    <time_frame>Week 0 - week 52</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs) during exposure to trial product</measure>
    <time_frame>Week 0 - week 57</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>From randomisation (week 0) to week 26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes during exposure to trial product</measure>
    <time_frame>Week 0 - week 57</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episode</measure>
    <time_frame>From randomisation (week 0) to week 26</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia episode during exposure to trial product</measure>
    <time_frame>Week 0 - week 57</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in amylase</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in amylase</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipase</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipase</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin-like growth factor 1 (IGF-1)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin-like growth factor 1 (IGF-1)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin-like growth factor binding protein 3 (IGFBP 3)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin-like growth factor binding protein 3 (IGFBP 3)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in calcitonin</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in calcitonin</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estradiol (for girls)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estradiol (for girls)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in testosterone (for boys)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in testosterone (for boys)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prolactin</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mIU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prolactin</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mIU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in thyroid stimulating hormone (TSH/thyrotropin)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mIU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in thyroid stimulating hormone (TSH/thyrotropin)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mIU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in follicle stimulating hormone (FSH)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in follicle stimulating hormone (FSH)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in luteinizing hormone (LH)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in luteinizing hormone (LH)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>μmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>μmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide antibodies</measure>
    <time_frame>Week 0 - week 57</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide antibodies with in vitro neutralising effect</measure>
    <time_frame>Week 0 to week 57</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide antibodies cross reacting with endogenous GLP-1</measure>
    <time_frame>Week 0 to week 57</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1</measure>
    <time_frame>Week 0 to week 57</time_frame>
    <description>Count of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide antibody level</measure>
    <time_frame>Week 0 to week 57</time_frame>
    <description>Percent bound/total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height velocity</measure>
    <time_frame>At week 26</time_frame>
    <description>cm/year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height velocity</measure>
    <time_frame>At week 52</time_frame>
    <description>cm/year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in height SDS</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>SDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone age assessment, X-ray</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pubertal assessment (Tanner staging)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Stage 1-5 where 5 is full sexual maturity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pubertal assessment (Tanner staging)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Stage 1-5 where 5 is full sexual maturity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse rate</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Beats/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse rate</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Beats/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose to post-dose (25 and 40 min) in lactate</measure>
    <time_frame>At week 12</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-dose to post-dose (25 and 40 min) in lactate</measure>
    <time_frame>At week 26</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Week 0 - week 52</time_frame>
    <description>L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cavg)</measure>
    <time_frame>Week 0 - week 52</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNAC plasma concentrations</measure>
    <time_frame>Week 0 - week 52</time_frame>
    <description>ng/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide - max. tolerated dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (semaglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral semaglutide</intervention_name>
    <description>Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.</description>
    <arm_group_label>Semaglutide - max. tolerated dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (semaglutide)</intervention_name>
    <description>Placebo treatment for 52 weeks.</description>
    <arm_group_label>Placebo (semaglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent from parent(s) or legally acceptable representative (LAR) and child&#xD;
             assent from the subject obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial.&#xD;
&#xD;
          -  Male or female, aged 10 to below 18 years at the day of randomisation&#xD;
&#xD;
          -  HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association&#xD;
             criteria and treated with:&#xD;
&#xD;
          -  stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or&#xD;
             the maximum tolerated dose for 56 days or longer prior to screening) or&#xD;
&#xD;
          -  stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin&#xD;
             is defined as basal insulin treatment equal to or more than 30 days prior to&#xD;
             screening, compared to the dose at screening, dose adjustments of ± 25% are allowed)&#xD;
             or&#xD;
&#xD;
          -  stable dose of basal insulin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes&#xD;
&#xD;
          -  Maturity onset diabetes of the young (MODY)&#xD;
&#xD;
          -  Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid&#xD;
             decarboxylase (anti-GAD) antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808-4124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-15125</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-15125</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haidari-Athens</city>
        <zip>GR-12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lamia</city>
        <zip>GR35100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Larissa</city>
        <zip>GR-41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penteli, Athens</city>
        <zip>15236</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-54643</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guntur</city>
        <state>Andhra Pradesh</state>
        <zip>522001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500072</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>4000016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Dehli</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolhapur</city>
        <zip>416008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thriruvananthapuram</city>
        <zip>695 032</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hazmieh</city>
        <zip>9615</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Puebla</city>
        <zip>72190</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rabat</city>
        <zip>10000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1315 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <zip>5223GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4400-129</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125373</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Greece</country>
    <country>India</country>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>North Macedonia</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

